Defensive lineman Desmond Watson shed 26 pounds in less than a month, but if selected in the NFL draft would still be ...

GLP-1 receptor agonists are effective weight-loss medications, but they may also decrease muscle mass, raising concerns about ...

Accounting for mortality as competing risk, the Afib burden trended numerically in favor of the GLP-1 RA group (HR 0.85, 95% ...

In this video at Obesity Medicine 2025, Harold E. Bays, MD, FOMA, FTOS, FACC, FASPC, FNLA, discusses highlights from his talk ...

Studies in neuroscience with applications to humans offer clues about what makes us start eating, and when we stop.

Novo Nordisk remains financially strong, but pricing pressures and CagriSema challenges limit near-term upside. Find out why ...

This week in Ozempic news: No more compounded GLP-1s, weight-loss pills are coming, and WeightWatchers is filing for ...

Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 ...

Novo Nordisk scored a legal win against compounders of its blockbuster GLP-1 drugs. But it may not end the copycats.

SGLT2 inhibitors and GLP-1 agonists are class 1 medications, but many Medicaid patients have challenges with access.

We recently published a list of the 11 Most Promising Small-Cap Stocks According to Analysts. In this article, we are going ...

El director ejecutivo de PepsiCo Inc., Ramón Laguarta, está acostumbrado a que le pregunten sobre el impacto de los exitosos ...